Costs and cost-effectiveness of 9-valent human papillomavirus (HPV) vaccination in two east african countries

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Kiatpongsan, Sorapop ^a,b,c   Kim, Jane J ^d  

^a HARVARD UNIVERSITY   (United States)

^b CHULALONGKORN UNIVERSITY   (Thailand)

^c CHULALONGKORN UNIVERSITY   (Thailand)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE; HUMAN PAPILLOMAVIRUS VACCINE L1, TYPE 6,11,16,18;

ARTICLE; CANCER IMMUNIZATION; CANCER PREVENTION; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; GROSS NATIONAL PRODUCT; KENYA; LIFE EXPECTANCY; MATHEMATICAL MODEL; PAPILLOMAVIRUS INFECTION; UGANDA; UTERINE CERVIX CANCER; ALPHAPAPILLOMAVIRUS; ECONOMICS; FEMALE; HEALTH CARE COST; HUMAN; IMMUNOLOGY; UTERINE CERVICAL NEOPLASMS;

HUMAN PAPILLOMAVIRUS;

ALPHAPAPILLOMAVIRUS; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HUMANS; KENYA; PAPILLOMAVIRUS VACCINES; UGANDA; UTERINE CERVICAL NEOPLASMS;

EID: 84908664147     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0106836     Document Type: Article

References (15)

1. Clifford GM, Smith JS, Aguado T, Franceschi S (2003) Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a metaanalysis. Br J Cancer 89: 101-105.
2. WHO/ICO Information Centre on Human Papilloma Virus (HPV) and Cervical Cancer (2012) HPV type distribution in invasive cervical cancer in Asia, Africa, Americas, Europe and Oceania continents. Available: http://www.who.int/hpvcentre/en/. Accessed 30 August 2012.
3. Bloomberg (2013) Pivotal Study of Investigational 9-Valent HPV Vaccine Demonstrates Additional Protection Against HPV-Related Disease. Available: http://www.bloomberg.com/article/2013-11-04/aHyETAS8v-iw.html. Accessed 28 November 2013.
4. Clinicaltrials.gov (2011) Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001). Available: http://clinicaltrials.gov/ct2/show/NCT00543543?term=V503&rank=6. Accessed 12 October 2011.
5. Kiatpongsan S, Campos NG, Kim JJ (2012) Potential benefits of secondgeneration human papillomavirus vaccines. PLoS One 7: e48426.
6. Campos NG, Kim JJ, Castle PE, Ortendahl JD, O'Shea M, et al. (2012) Health and economic impact of HPV 16/18 vaccination and cervical cancer screening in Eastern Africa. Int J Cancer 130: 2672-2684.
7. Kim JJ, Kuntz KM, Stout NK, Mahmud S, Villa LL, et al. (2007) Multiparameter calibration of a natural history model of cervical cancer. Am J Epidemiol 166: 137-150.
8. Denny L, Kuhn L, Pollack A, Wainwright H, Wright TC, Jr. (2000) Evaluation of alternative methods of cervical cancer screening for resource-poor settings. Cancer 89: 826-833.
9. WHO (2001) Macroeconomics and health: investing in health for economic development. Report of the Commission on Macroeconomics and Health.
10. World Bank World Development Indicators, WDI Online. Available: http://www.worldbank.org/. Accessed 24 January 2010.
11. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, et al. (2009) Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374: 301-314.
12. National Cancer Institute. HPV and Cancer. Available: http://www.cancer.gov/cancertopics/factsheet/Risk/HPV. Accessed 28 November 2013.
13. McNeil D (2013) Cancer Vaccines Get a Price Cut in Poor Nations. The New York Times. Available: http://www.nytimes.com/2013/05/10/health/prices-cut-for-hpv-cervical-cancer-vaccines-for-neediest.html?pagewanted = all&-r= 1&. Accessed 19 May 2013.
14. GAVI (2013) Kenya first country to protect girls against cervical cancer with GAVI support. Available: http://www.gavialliance.org/library/news/pressreleases/2013/kenya-first-country-to-protect-girls-against-cervical-cancer-with-gavi-support/. Accessed 19 May 2013.
15. Goldie SJ, O'Shea M, Campos NG, Diaz M, Sweet S, et al. (2008) Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries. Vaccine 26: 4080-4093.